ARDELYX, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.335 USD | -0.24% |
|
-1.70% | +2.42% |
| May. 24 | Ardelyx Shares Fall; Chief Commercial Officer Resigns | MT |
| May. 23 | Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer | CI |
Presenter SpeechMichael Raab (Executives)Well, good morning. Thank you all for coming today to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.35
USD
Average target price
13.83
USD
Spread / Average Target
+117.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.42% | 1.49B | |
| +16.98% | 124B | |
| +18.84% | 112B | |
| +3.52% | 22.94B | |
| -11.47% | 17.02B | |
| -16.50% | 16.88B | |
| -39.57% | 16.87B | |
| +3.61% | 13.63B | |
| +24.02% | 11.61B | |
| +107.16% | 10.31B |
- Stock Market
- Equities
- ARDX Stock
- News Ardelyx, Inc.
- Transcript : Ardelyx, Inc. - Analyst/Investor Day
